Therefore, an alternate strategy to address the unmet therapeutic need of lung fibrosis is necessary, and the development and clinical application of novel HSP27 inhibitors will provide an additional therapeutic option for overcoming IPF. Here, HSPB1 is linked to pulmonary fibrosis.